Pharmacogenetics in Cardiovascular Diseases

摘要: Data from randomized, controlled, clinical trials historically drive treatment decisions for cardiovascular diseases. However, it is now well recognized that an individual’s genotype significantly influences his or her response to numerous treatments. As such, there a growing role personalized medicine in this therapeutic area. Genotype therapies primarily by affecting pharmacokinetics (i.e., disposition), pharmacodynamics sensitivity the drug), both. At least 12 drugs have genetic information included their U.S. Food and Drug Administration–approved labeling. The strongest pharmacogenomic evidence exists clopidogrel warfarin. Some institutions are already embracing genotype-guided therapy these drugs. Barriers other include demand further of utility such approach concerns about third-party reimbursement testing. Clinical ongoing address issue utility, results may lead greater acceptance pharmacogenomics clinicians policy makers.